Status:
UNKNOWN
Evaluation of the Predictive Value of Blood Levels of Angiopoietin 1 and Endothelial Internal Tunica Cell Kinase 2 in Patients With Ovarian Cancer Treated With Chemotherapy Associated to Bevacizumab
Lead Sponsor:
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Collaborating Sponsors:
Ospedale SS Giovanni e Paolo, Venezia
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
This is a monocentric prospective observational pilot study of translational research in women with advanced ovarian epithelial cancer. The main purpose of this study is to evaluate the predictive val...
Eligibility Criteria
Inclusion
- Patients ≥ 18 years old
- Diagnosis of histologically confirmed advanced epithelial ovarian carcinoma
- Women eligible for treatment with a chemotherapy regimen in combination to bevacizumab (Cohort A)
- Women eligible for treatment with a chemotherapy regimen not associated to antiangiogenic drugs (Cohort B)
- Evaluable disease according to RECIST 1.1 criteria
- Patient informed consent signature prior to any study-specific procedure
Exclusion
- History of other malignancy within 5 years prior to study entry (except for cutaneous basal cell carcinoma or adequately treated carcinoma in situ of the cervix ).
Key Trial Info
Start Date :
October 12 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04770376
Start Date
October 12 2020
End Date
December 1 2023
Last Update
December 29 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, SSD Oncologia Medica Addarii
Bologna, Italy, 40138